Files in This Item:


Title: Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease
Authors: El Karaksy, H.
El Sayed, R.
El Raziky, M.
El Koofy,N.
Mansour, S.
Issue Date: 2008
Language: English
Abstract: The aim of the study was to determine the prevalence of anti-hepatitis A virus [anti-HAV] antibodies among 172 children with chronic liver disease, and to calculate the cost- effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years
Description: 804-809
Keywords: Costs and Cost Analysis
Mass Screening
Hepatitis A Antibodies
Age Distribution
Liver Diseases
Chronic Disease
Subject: Hepatitis A Vaccines
ISSN: 1020-3397
Other Identifiers:
Appears in Collections:EMRO Journal Articles (EMHJ)

Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated.